Insulet Corporation (NASDAQ:PODD) EVP Charles Alpuche acquired 2,500 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were bought at an average cost of $58.08 per share, with a total value of $145,200.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Insulet Corporation (PODD) traded down 1.09% during trading on Thursday, reaching $57.97. The company’s stock had a trading volume of 474,171 shares. The firm’s market capitalization is $3.37 billion. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $58.99. The stock’s 50-day moving average is $54.28 and its 200 day moving average is $46.96.

Insulet Corporation (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The business had revenue of $110 million for the quarter, compared to the consensus estimate of $106.23 million. During the same period last year, the business earned ($0.08) EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. On average, analysts predict that Insulet Corporation will post ($0.50) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Charles Alpuche Acquires 2,500 Shares of Insulet Corporation (PODD) Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/07/charles-alpuche-acquires-2500-shares-of-insulet-corporation-podd-stock.html.

Several hedge funds have recently modified their holdings of PODD. Nationwide Fund Advisors raised its stake in shares of Insulet Corporation by 238.8% in the 1st quarter. Nationwide Fund Advisors now owns 122,304 shares of the medical instruments supplier’s stock valued at $5,270,000 after acquiring an additional 86,210 shares in the last quarter. Strs Ohio raised its stake in shares of Insulet Corporation by 73.9% in the 1st quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after acquiring an additional 1,700 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Insulet Corporation by 943.0% in the 1st quarter. Russell Investments Group Ltd. now owns 24,230 shares of the medical instruments supplier’s stock valued at $1,044,000 after acquiring an additional 21,907 shares in the last quarter. Swiss National Bank raised its stake in shares of Insulet Corporation by 1.9% in the 1st quarter. Swiss National Bank now owns 94,300 shares of the medical instruments supplier’s stock valued at $4,063,000 after acquiring an additional 1,800 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Insulet Corporation by 2.0% in the 1st quarter. UBS Asset Management Americas Inc. now owns 192,168 shares of the medical instruments supplier’s stock valued at $8,281,000 after acquiring an additional 3,775 shares in the last quarter.

A number of analysts recently issued reports on the stock. Zacks Investment Research raised shares of Insulet Corporation from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a research report on Tuesday, July 18th. Piper Jaffray Companies reissued an “overweight” rating and set a $47.00 target price on shares of Insulet Corporation in a research report on Monday, May 22nd. B. Riley reissued a “neutral” rating and set a $44.00 target price on shares of Insulet Corporation in a research report on Sunday, May 14th. BTIG Research downgraded shares of Insulet Corporation from a “buy” rating to a “neutral” rating in a research report on Monday, July 17th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Insulet Corporation in a research report on Friday, June 16th. Eight research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Insulet Corporation presently has an average rating of “Buy” and an average target price of $50.46.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.